Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2021 / N 4

Клинико-экономическое исследование применения фиксированной комбинации алоглиптин + пиоглитазон у пациентов с сахарным диабетом 2-го типа
С.В. Недогода, А.С. Саласюк, И.Н. Барыкина, В.О. Лутова, Е.А. Попова

Список литературы

1. Министерство здравоохранения РФ; Российская ассоциация эндокринологов; Национальный медицинский исследовательский центр эндокринологии. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. Дедова И.И., Шестаковой М.В., Майорова А.Ю. 10-й выпуск (дополненный). М., 2021. 236 с.
2. Dedov I, Shestakova M, Benedetti MM, Simon D, Pakhomov I, Galstyan G. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Research and Clinical Practice 2016 May;115:90-5.
3. International Diabetes Federation. IDF diabetes atlas, ninth edition. 2019. Brussels, Belgium: IDF; 2019. 179 p. Available from: https://diabetesatlas.org/idfawp/resource-files/2019/07/IDF_diabetes_atlas_ninth_edition_en.pdf Accessed 2022 Feb 02.
4. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovascular Diabetology 2018 Aug;17(1):122.
5. DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diabetes & Vascular Disease Research 2019 Mar;16(2):13343.
6. Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open 2017;7:e013927.
7. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O’Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. The New England Journal of Medicine 2016 Apr;374(14):1321-31.
8. AbdelMassih AF, Ashraf A, Ismail HA, AbdelAzeim B, Barsoum IH, Girgis S, Afdal G, AbdelAzeim N, Afdal P, Menshawey E, Menshawey R, Badr K, Arsanyous M. Effect of pioglitazone, as antidiabetic agent, on atheroma regression in type 2 diabetic patients: a systematic review and meta-analysis. Beni-Suef University Journal of Basic and Applied Sciences 2021 Feb;10(1):1-6.
9. Pratley RE, Reusch JEB, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Current Medical Research and Opinion 2009 Oct;25(10):2361.
10. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism 2012;97(5):1615-22.
11. Wang B, Sun Y, Sang Y, Liu X, Liang J. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: a system review and meta-analysis. Medicine (Baltimore) 2018 Nov;97(46):e12633.
12. Шестакова М.В., Анциферов М.Б., Аметов А.С., Галстян Г.Р., Демидова Т.Ю., Мкртумян А.М., Петунина Н.А. Возможности применения фиксированной комбинации алоглиптина и пиоглитазона в условиях современной парадигмы лечения сахарного диабета 2 типа. Сахарный диабет 2021;24(2):193-7.
13. Kim JM, Kim SS, Kim JH, Kim MK, Kim TN, Lee SH, Lee CW, Park JY, Kim ES, Lee KJ, Choi YS, Kim DK, Kim IJ. Efficacy and safety of pioglitazone versus glimepiride after metformin and alogliptin combination therapy: a randomized, open-label, multicenter, parallel-controlled study. Diabetes & Metabolism Journal 2020 Feb;44(1):67-77.
14. Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48(6):1093-104.
15. Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R, Edwards G, Johns D; GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005 Mar;28(3):544-50.
16. Hanefeld M, Pfützner A, Forst T, Lübben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Current Medical Research and Opinion 2006 Jun;22(6):1211-5.
17. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D’Agostino RB Sr, Perez A, Provost JC, Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006 Dec;296(21):2572-81.
18. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008 Apr;299(13):1561-73.
19. Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Research and Clinical Practice 2015 Oct;110(1):75-81.
20. Министерство здравоохранения РФ. Российская ассоциация эндокринологов. Клинические рекомендации. Сахарный диабет 2 типа у взрослых. Кодирование по Международной статистической классификации болезней и проблем, связанных со здоровьем: E11.2, E11.3, E11.4, E11.5, E11.6, E11.7, E11.8, E11.9. Год утверждения: 2019. Возрастная категория: взрослые. Год окончания действия: 2021. М., 2019. 195 с. Доступно по: https://cr.minzdrav.gov.ru/recomend/290_1 Ссылка активна на 02.02.2022.
21. Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет 2018;21(3):144-59.
22. Федеральный регистр сахарного диабета РФ. Доступно по: http://sd.diaregistry.ru Ссылка активна на 02.02.2022.

References

1. Ministry of Health of the Russian Federation; Russian Association of Endocrinologists; National Medical Research Center of Endocrinology. Standards of specialized diabetes care. Dedov II, Shestakov MV, Mayorov AYu, editors. 10th ed., revised. Moscow, 2021. 236 p. (In Russian).
2. Dedov I, Shestakova M, Benedetti MM, Simon D, Pakhomov I, Galstyan G. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Research and Clinical Practice 2016 May;115:90-5.
3. International Diabetes Federation. IDF diabetes atlas, ninth edition. 2019. Brussels, Belgium: IDF; 2019. 179 p. Available from: https://diabetesatlas.org/idfawp/resource-files/2019/07/IDF_diabetes_atlas_ninth_edition_en.pdf Accessed 2022 Feb 02.
4. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovascular Diabetology 2018 Aug;17(1):122.
5. DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diabetes & Vascular Disease Research 2019 Mar;16(2):13343.
6. Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open 2017;7:e013927.
7. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O’Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. The New England Journal of Medicine 2016 Apr;374(14):1321-31.
8. AbdelMassih AF, Ashraf A, Ismail HA, AbdelAzeim B, Barsoum IH, Girgis S, Afdal G, AbdelAzeim N, Afdal P, Menshawey E, Menshawey R, Badr K, Arsanyous M. Effect of pioglitazone, as antidiabetic agent, on atheroma regression in type 2 diabetic patients: a systematic review and meta-analysis. Beni-Suef University Journal of Basic and Applied Sciences 2021 Feb;10(1):1-6.
9. Pratley RE, Reusch JEB, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Current Medical Research and Opinion 2009 Oct;25(10):2361.
10. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism 2012;97(5):1615-22.
11. Wang B, Sun Y, Sang Y, Liu X, Liang J. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: a system review and meta-analysis. Medicine (Baltimore) 2018 Nov;97(46):e12633.
12. Shestakova MV, Antsiferov MB, Ametov AS, Galstyan GR, Demidova TYu, Mkrtumyan AM, Petunina NA. Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment. Diabetes Mellitus 2021;24(2):193-7 (In Russian).
13. Kim JM, Kim SS, Kim JH, Kim MK, Kim TN, Lee SH, Lee CW, Park JY, Kim ES, Lee KJ, Choi YS, Kim DK, Kim IJ. Efficacy and safety of pioglitazone versus glimepiride after metformin and alogliptin combination therapy: a randomized, open-label, multicenter, parallel-controlled study. Diabetes & Metabolism Journal 2020 Feb;44(1):67-77.
14. Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48(6):1093-104.
15. Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R, Edwards G, Johns D; GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005 Mar;28(3):544-50.
16. Hanefeld M, Pfützner A, Forst T, Lübben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Current Medical Research and Opinion 2006 Jun;22(6):1211-5.
17. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D’Agostino RB Sr, Perez A, Provost JC, Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006 Dec;296(21):2572-81.
18. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008 Apr;299(13):1561-73.
19. Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Research and Clinical Practice 2015 Oct;110(1):75-81.
20. Ministry of Health of the Russian Federation. Russian Association of Endocrinologists. Clinical recommendations. Type 2 diabetes mellitus in adults. Coding according to the International statistical classification of diseases and health-related problems (ICD): E11.2, E11.3, E11.4, E11.5, E11.6, E11.7, E11.8, E11.9. Year of approval: 2019. Age category: adults. Year of expiration: 2021. Moscow, 2019. 195 p. Available from: https://cr.minzdrav.gov.ru/recomend/290_1 Accessed 2022 Feb 02. (In Russian).
21. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA. Diabetes mellitus in the Russian Federation: prevalence, morbidity, mortality, parameters of carbohydrate metabolism and structure of hypoglycemic therapy according to the Federal register of diabetes mellitus, status 2017. Diabetes Mellitus 2018;21(3):144-59 (In Russian).
22. Federal register of diabetes mellitus of the Russian Federation. Available from: http://sd.diaregistry.ru Accessed 2022 Feb 02. (In Russian).
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]